Ứng dụng mHealth để cải thiện kết quả điều trị cho bệnh nhân lao kháng đa thuốc tại Việt Nam: giao thức đánh giá kinh tế cho thử nghiệm V-SMART
Tóm tắt
Từ khóa
Tài liệu tham khảo
citation_title=Tuberculosis fact sheet;citation_year=2018
citation_title=Global tuberculosis report 2022;citation_year=2022
citation_title=Tuberculosis profile: Viet Nam. TB country, regional and global profiles;citation_year=2022
citation_title=Report of Vietnam National Tuberculosis Programme, N.T. Program;citation_year=2021
citation_journal_title=Int J Tuberc Lung Dis;citation_author=RH. Berhanu;citation_author=K. Schnippel;citation_author=R. Kularatne;citation_title=Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia;citation_pages=358-62;citation_volume=22;citation_year=2018;citation_pmid=http://www.n
citation_journal_title=Infect Dis Poverty;citation_title=Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia’s implementation of universal health coverage;citation_volume=7;citation_year=2018
citation_journal_title=PLoS Med;citation_title=Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study;citation_volume=11;citation_year=2014
citation_title=WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update;citation_year=2022
citation_journal_title=Indian J Med Res;citation_author=S. Sharma;citation_author=K. Dheda;citation_title=World health organization, WHO consolidated guidelines on drug-resistant tuberculosis treatment;citation_pages=309;citation_volume=149;citation_year=2019;citation_pmid=http://www.n
citation_journal_title=Am J Ther;citation_author=S. Wu;citation_author=Y. Zhang;citation_author=F. Sun;citation_title=Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis;citation_pages=e521-30;citation_volume=23;citation_year=2016;citation_pmid=24284652;citation_doi=10.1097/01.mjt.0000433951.09030.5a
citation_journal_title=Lancet Respir Med;citation_author=Z. Lan;citation_author=N. Ahmad;citation_author=P. Baghaei;citation_title=Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis;citation_pages=383-94;citation_volume=8;citation_year=2020
citation_journal_title=Med Sci Monit;citation_author=Y. Zhang;citation_author=S. Wu;citation_author=Y. Xia;citation_title=Adverse events associated with treatment of multidrug-resistant tuberculosis in China: an ambispective cohort study;citation_pages=2348-56;citation_volume=23;citation_year=2017
citation_journal_title=BMC Infect Dis;citation_title=Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda;citation_volume=23;citation_year=2023
citation_journal_title=PLoS One;citation_title=Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter Injectable based regimen in West Java Indonesia;citation_volume=17;citation_year=2022
citation_journal_title=Infect Drug Resist;citation_author=T. Belachew;citation_author=S. Yaheya;citation_author=N. Tilahun;citation_title=Multidrug-resistant tuberculosis treatment outcome and associated factors at the University of Gondar comprehensive specialized hospital: a ten-year retrospective study;citation_pages=2891-9;citation_volume=15;citation_year=2022
citation_journal_title=BMC Infect Dis;citation_title=Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh city: a retrospective study;citation_volume=20;citation_year=2020
citation_journal_title=BMJ Open;citation_title=Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti region, Ghana: a retrospective, cross-sectional study;citation_volume=12;citation_year=2022
citation_journal_title=Clin Microbiol Infect;citation_author=A. Javaid;citation_author=I. Ullah;citation_author=H. Masud;citation_title=Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study;citation_pages=612-7;citation_volume=24;citation_year=2018;citation_pmid=http://www.n
citation_journal_title=Infect Drug Resist;citation_author=W. Xing;citation_author=R. Zhang;citation_author=W. Jiang;citation_title=Adherence to multidrug resistant tuberculosis treatment and case management in Chongqing, China - a mixed method research study;citation_pages=999-1012;citation_volume=14;citation_year=2021
citation_journal_title=Afr Health Sci;citation_author=C. Batte;citation_author=MS. Namusobya;citation_author=R. Kirabo;citation_title=Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago national referral hospital, Kampala, Uganda;citation_pages=238-47;citation_volume=21;citation_year=2021
citation_journal_title=BMC Pulm Med;citation_title=Determinant factors for loss to follow-up in drug-resistant tuberculosis patients: the importance of psycho-social and economic aspects;citation_volume=21;citation_year=2021
citation_title=WHO Global Observatory for eHealth, mHealth: new horizons for health through mobile technologies: second global survey on eHealth;citation_year=2011
citation_journal_title=Eur Heart J Qual Care Clin Outcomes;citation_author=Y. Gandapur;citation_author=S. Kianoush;citation_author=HM. Kelli;citation_title=The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review;citation_pages=237-44;citation_volume=2;citation_year=2016
citation_journal_title=Int J Clin Pract;citation_author=H. Anglada-Martinez;citation_author=G. Riu-Viladoms;citation_author=M. Martin-Conde;citation_title=Does mHealth increase adherence to medication? Results of a systematic review;citation_pages=9-32;citation_volume=69;citation_year=2015;citation_pmid=25472682;citation_doi=10.1111/ijcp.12582
citation_journal_title=J Med Internet Res;citation_title=Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review;citation_volume=17;citation_year=2015
citation_journal_title=Curr Hypertens Rep;citation_title=Effectiveness of mHealth interventions in improving medication adherence among people with hypertension: a systematic review;citation_volume=20;citation_year=2018
citation_journal_title=Eur Respir J;citation_title=Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review;citation_volume=53;citation_year=2019
citation_journal_title=BMC Med;citation_title=Economic analyses to inform public health decision-making for tuberculosis: the role of understanding implementation;citation_volume=17;citation_year=2019
citation_journal_title=Value Health;citation_author=SD. Sullivan;citation_author=JA. Mauskopf;citation_author=F. Augustovski;citation_title=Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force;citation_pages=5-14;citation_volume=17;citation_year=2014;citation_pmid=24438712;citation_doi=10.1016/j.jval.2013.08.2291
citation_journal_title=Environ Health Prev Med;citation_title=A review of Vietnam’s healthcare reform through the direction of healthcare activities (DOHA);citation_volume=22;citation_year=2017
citation_journal_title=BMJ Open;citation_title=Harnessing new mHealth technologies to strengthen the management of multidrug-resistant tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial;citation_volume=12;citation_year=2022
citation_journal_title=Glob Health Action;citation_title=Step-by-step guideline for disease-specific costing studies in Low- and middle-income countries: a mixed methodology;citation_volume=7;citation_year=2014
citation_journal_title=Pharmacoeconomics;citation_author=M. Krol;citation_author=W. Brouwer;citation_author=F. Rutten;citation_title=Productivity costs in economic evaluations: past, present, future;citation_pages=537-49;citation_volume=31;citation_year=2013;citation_pmid=23620213;citation_doi=10.1007/s40273-013-0056-3
citation_journal_title=Asia Pacific Journal of Public Health;citation_journal_abbrev=Asia Pac J Public Health;citation_author=RE. Watkins;citation_author=AJ. Plant;citation_author=D. Sang;citation_title=Development of a Vietnamese Version of the Short Form-36 Health Survey;citation_pages=118-123;citation_volume=12;citation_year=2000;citation_issue=2;citation_pmid=11841039;citation_doi=10.1177/101053950001200211
citation_journal_title=J Aging Health;citation_author=Q. Ngo-Metzger;citation_author=DH. Sorkin;citation_author=CM. Mangione;citation_title=Evaluating the SF-36 health survey (version 2) in older Vietnamese Americans;citation_volume=20;citation_year=2008;citation_pmid=18381886;citation_doi=10.1177/0898264308315855
citation_journal_title=Pharmacoeconomics;citation_author=R. Faria;citation_author=M. Gomes;citation_author=D. Epstein;citation_title=A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials;citation_pages=1157-70;citation_volume=32;citation_year=2014;citation_pmid=25069632;citation_doi=10.1007/s40273-014-0193-3
citation_title=Making choices in health: WHO guide to cost-effectiveness analysis;citation_year=2003
citation_journal_title=Value Health;citation_author=OT. Due;citation_author=A. Thakkinstian;citation_author=M. Thavorncharoensap;citation_title=Cost-utility analysis of direct-acting antivirals for treatment of chronic hepatitis C genotype 1 and 6 in Vietnam;citation_pages=1180-90;citation_volume=23;citation_year=2020
citation_journal_title=AIDS Behav;citation_author=NA. Blackburn;citation_author=VF. Go;citation_author=Q. Bui;citation_title=The cost-effectiveness of adapting and implementing a brief intervention to target frequent alcohol use among persons with HIV in Vietnam;citation_pages=2108-19;citation_volume=25;citation_year=2021
citation_journal_title=Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research;citation_journal_abbrev=Value Health;citation_author=JA. Mauskopf;citation_author=SD. Sullivan;citation_author=L. Annemans;citation_title=Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.;citation_pages=336-347;citation_volume=10;citation_year=2007;citation_issue=5;citation_pmid=17888098;citation_doi=10.1111/j.1524-4733.2007.00187.x
citation_journal_title=Value Health;citation_author=SD. Sullivan;citation_author=JA. Mauskopf;citation_author=F. Augustovski;citation_title=Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force;citation_pages=5-14;citation_volume=17;citation_year=2014;citation_pmid=24438712;citation_doi=10.1016/j.jval.2013.08.2291
citation_journal_title=BMC Infect Dis;citation_title=Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: a retrospective cohort study;citation_volume=22;citation_year=2022
citation_journal_title=JMIR Mhealth Uhealth;citation_title=Long-term effectiveness of a Smartphone App for improving healthy lifestyles in general population in primary care: randomized controlled trial (evident II study);citation_volume=6;citation_year=2018
citation_journal_title=J Med Internet Res;citation_title=The association between logging steps using a Website, App, or Fitbit and engaging with the 10,000 steps physical activity program: observational study;citation_volume=23;citation_year=2021